Serinus Biosciences
Combinations therapy by rational design
What they do
Cancer treatments often fail because tumors evolve resistance, and designing effective, safe combination therapies to overcome that resistance is difficult and slow.
An explainable, systems-biology-informed AI platform that models resistance mechanisms and identifies rational drug combinations and molecules to block escape pathways.
Biopharma companies and oncology drug developers designing combination therapies for cancer.
Founders
Prior to founding Serinus, Adam gained over 10 years of entrepreneurship experience including a Microsoft R&D Fellowship and Flagship Pioneering Ideation Fellowship. Adam is passionate about developing advanced AI models for biological research that will bring medicine to scale. Adam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and dual major BSc in computer science and neuroscience from Bar-Ilan University.
After five years as a paramedic, Max left clinical medicine to develop new treatments for the millions of patients without access to effective medications. He studied applied math and biology at Brown University, statistics at Cambridge University, and is completing his PhD in computational biology at MIT. His research has appeared in prestigious journals including Science, Nature Biotechnology, and Nature Neuroscience and has been recognized with national and international awards.
Company timeline
- Founded2022
- YC batchSummer 2022
- StatusActive
- Team size6 people
- LocationNew York, NY, USA
Similar startups
